ABSTRACT NUMBER: ESOC2026LB73 LB73 - ENDOVASCULAR TREATMENT FOR MILD ISCHEMIC STROKE WITH ACUTE ANTERIOR CIRCULATION LARGE VESSEL OCCLUSION:A MULTICENTER, PROSPECTIVE, RANDOMIZED, CLINICAL TRIAL (MILD-MT)

作者
J W Liu,Zeguang Ren,Pengfei Yang,Wenhuo Chen,Tingyu Yi,Pengfei Xing,Meihua Wu
出处
期刊:European stroke journal [SAGE Publishing]
卷期号:11 (Supplement_1): i990-i990 被引量:2
标识
DOI:10.1093/esj/aakag023.1859
摘要

Abstract Background and aims Acute ischemic stroke (AIS) with National Institutes of Health Stroke Scale (NIHSS) score < 6 is termed as mild stroke. The benefit of endovascular therapy (EVT) for mild stroke patients caused by large vessel occlusion (LVO) is uncertain.This trial aims to explore the efficacy and safety of EVT in patients with mild ischemic stroke caused by acute anterior circulation LVO based on perfusion imaging screening. Methods MILD-MT trial is a multicenter, prospective, randomized, open-label, blinded endpoint (PROBE) trial designed to evaluate whether EVT combined with best medical management (EVT+BMM) is superior to BMM alone in mild stroke patients due to anterior circulation LVO patients are at high risk early neurological deterioration and could be benefit from screening with perfusion imaging. The primary efficacy outcome is the rate of excellent outcome at 90±7 (mRS score 0-1) days. Results Since its initiation in January 2024, the trial completed enrollment of all 300 patients by October, 2025 across 26 hospitals in China. All patients have completed the follow-up.The trial is scheduled to lock data by late March 2026. Study findings will be presented at this conference. Conclusions The MILD-MT trial is the first RCT to investigate the efficacy and safety of EVT in mild stroke patients caused by LVO screening with perfusion imaging.The results of this study will result in substantial evidence regarding the efficacy and safety of EVT for mild patients with AIS-LVO and large salvageable volume within 24 hours from symptom onset. Conflict of interest

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
HMMM发布了新的文献求助10
1秒前
Orange的应助被刻苦的雨莲采纳,获得30
1秒前
1秒前
要减肥的春天完成签到,获得积分10
1秒前
towanda发布了新的文献求助10
1秒前
1秒前
1秒前
1秒前
1秒前
zydf发布了新的文献求助10
1秒前
1秒前
麻花精发布了新的文献求助10
1秒前
小石头发布了新的文献求助10
2秒前
充电宝的应助被虚幻大有采纳,获得10
2秒前
wel233完成签到,获得积分10
2秒前
3秒前
3秒前
aaaa的应助被Arden采纳,获得30
3秒前
3秒前
Xenia发布了新的文献求助10
4秒前
linjunqi发布了新的文献求助10
4秒前
5秒前
ZTLY完成签到,获得积分10
5秒前
Youdge的应助被gustavo采纳,获得20
5秒前
5秒前
5秒前
峰成给峰成的求助进行了留言
5秒前
6秒前
不会游泳发布了新的文献求助10
6秒前
bbb发布了新的文献求助10
6秒前
芋圆发布了新的文献求助10
7秒前
7秒前
7秒前
蓝桉完成签到,获得积分10
7秒前
段书芹完成签到,获得积分10
7秒前
7秒前
ddiou完成签到,获得积分10
7秒前
大个的应助被乳酸菌饮品采纳,获得10
7秒前
7秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Energie-Contracting 1500
Représentation chimique de la structure des kérogènes et des asphaltènes en fonction de leur origine et de leur degré d'évolution 1000
Klimaschutzrecht durch den Energiesektor im Mehrebenensystem – Ein Rechtsvergleich 1000
Oncology Clinical Trials: Successful Design, Conduct, and Analysis, Second Edition 800
Ecotourism 400
Comprehensive Heterocyclic Chemistry IV 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8060928
求助须知:如何正确求助?哪些是违规求助? 9485330
关于积分的说明 21330887
捐赠科研通 7629494
什么是DOI,文献DOI怎么找? 3395780
关于科研通互助平台的介绍 2526650
邀请新用户注册赠送积分活动 2434341